ecancermedicalscience

Review

Current management approach to hidradenocarcinoma: a comprehensive review of the literature

19 Mar 2015
Abhishek Soni, Nupur Bansal, Vivek Kaushal, Ashok Kr Chauhan

Hidradenocarcinoma is a rare malignant adnexal tumour which arises from the intradermal duct of eccrine sweat glands. The head and neck are the most common sites of hidradenocarcinoma, but rarely it can occur on the extremities. As it is an aggressive tumour, regional lymph nodes and distant viscera are the most common sites of metastasis. Diagnosis is confirmed by histopathology and immunohistochemistry. Hidradenocarcinoma should be differentiated from benign and malignant adnexal tumours. Being an aggressive and rare tumour, no uniform treatment guidelines have been documented so far for metastatic hidradenocarcinoma. Wide local excision is the mainstay of the treatment, but because of high local recurrence, radiotherapy in a dose of 50Gy–70Gy and/or 5-fluorouracil and capecitabine-based combination chemotherapy may be given to further improve local control. Other treatment strategies are targeted therapies like trastuzumab, EGFR inhibitors, PI3K/Akt/mTOR pathway inhibitors, hormonal agents like antiandrogens, electrochemotherapy, or clinical trials.

Related Articles

Nikhil Bathija, Rohit Mahajan, Anil Kumar Goel, Siva Ranjani, Mounika Sirimalla, Gourav Kaushal, Sapna Marcus, Shilpa Jain, Madhur Verma, Deep Shikha, Korukonda Vinod Kumar, Jyoti Sharma
Pavan Raju Kola, Amith Paruchuri, Nimisha Preman, Hemavathi Baskarane, Vishakha Hooda, Aparna Sharma, Ishaan Gupta, Saran Kumar, Shilpi Minocha, Pranay Tanwar, Mohit Kumar Divakar, Atul Batra
Loreto Fernández-González, Rodrigo Lagos, Piero Bettoli, Loreto Moreira, Jaime Sapag, David Kissane
Jaden Paltoo, Danusha Vinoraj, Elizaveta Klekovkina, Alyssa Tilly, John Bosco, John Lule, Akosua Agyemang, Maria Chikasema, Selena Kleber, Mary Goombs, Iddi Matovu, Craig Sinclair, Wendy G. Lichtenthal, Lesley Chalklin, Eve Namisango, Gary Rodin